Aethlon Medical
AEMD
12 hedge funds and large institutions have $1.54M invested in Aethlon Medical in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 2 reducing their positions, and 3 closing their positions.
22% more capital invested
Capital invested by funds: $1.26M → $1.54M (+$275K)
0% more funds holding
Funds holding: 12 → 12 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| 1 |
Bank of New York Mellon
New York
|
+$43.4K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
+$14.5K |
Top Sellers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$159K |
| 2 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$43.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$17K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$16K |
| 5 |
VF
Virtu Financial
New York
|
-$13K |
AEMD Hedge Fund Activity: Q4 2018 in Review
12 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Aethlon Medical (AEMD) for Q4 2018, worth a combined $1.54M — up 22% from $1.26M a quarter earlier.
Fund positioning in AEMD was balanced in Q4 2018: 3 funds opened new positions, 3 closed out, 0 added to existing stakes and 2 trimmed.
The largest buyer was Bank of New York Mellon, opening a new position worth an estimated $43.4K. The largest seller was Vanguard Group, cutting an estimated $159K.
- 12 institutional investors held Aethlon Medical (AEMD) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $1.54M of Aethlon Medical stock for Q4 2018, up 22% quarter-over-quarter.
- 3 funds opened new Aethlon Medical positions in Q4 2018 and 3 closed out, a net change of 0 holders.
- The largest Aethlon Medical buyer in Q4 2018 was Bank of New York Mellon, an estimated $43.4K added.
- The largest Aethlon Medical seller in Q4 2018 was Vanguard Group, an estimated $159K sold.
Based on aggregated 13F filings for Q4 2018.